- Home
- LDWY vs HCWB Comparison
LDWY vs HCWB Comparison
Compare LDWY & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LDWY | HCWB |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.5M |
| IPO Year | 1991 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LDWY | HCWB |
|---|---|---|
| Price | $3.38 | $1.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 48.6K | ★ 151.3K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $69,769,000.00 | $422,026.00 |
| Revenue This Year | N/A | $178.64 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.84 | ★ N/A |
| Revenue Growth | ★ 121.91 | N/A |
| 52 Week Low | $3.11 | $1.52 |
| 52 Week High | $6.19 | $41.20 |
Technical Indicators
Market Signals| Indicator | LDWY | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 34.40 |
| Support Level | $3.11 | $1.52 |
| Resistance Level | $3.99 | $2.15 |
| Average True Range (ATR) | 0.33 | 0.18 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 16.34 | 50.36 |
Price Performance
Historical ComparisonAbout LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.